+

WO2008069992A3 - Procédé et trousse pour administration intracellulaire - Google Patents

Procédé et trousse pour administration intracellulaire Download PDF

Info

Publication number
WO2008069992A3
WO2008069992A3 PCT/US2007/024681 US2007024681W WO2008069992A3 WO 2008069992 A3 WO2008069992 A3 WO 2008069992A3 US 2007024681 W US2007024681 W US 2007024681W WO 2008069992 A3 WO2008069992 A3 WO 2008069992A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit
intracellular delivery
cell
transfection agents
dimethylsulfoxide
Prior art date
Application number
PCT/US2007/024681
Other languages
English (en)
Other versions
WO2008069992A2 (fr
Inventor
Anja Nohe
Jay Nadeau
Original Assignee
Univ Maine Sys Board Trustees
Anja Nohe
Jay Nadeau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maine Sys Board Trustees, Anja Nohe, Jay Nadeau filed Critical Univ Maine Sys Board Trustees
Publication of WO2008069992A2 publication Critical patent/WO2008069992A2/fr
Publication of WO2008069992A3 publication Critical patent/WO2008069992A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un procédé et une trousse permettant l'administration d'un ou de plusieurs agents de transfection dans une cellule, y compris le noyau de cette cellule. Le procédé consiste à exposer la cellule à un ou plusieurs agents de transfection, qui peuvent être des points quantiques ou des polypeptides, par exemple, du diméthylsulfoxyde et un rayonnement électromagnétique. La trousse contient un ou plusieurs réactifs et des instructions permettant la mise en œuvre du procédé.
PCT/US2007/024681 2006-12-01 2007-11-30 Procédé et trousse pour administration intracellulaire WO2008069992A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86817806P 2006-12-01 2006-12-01
US60/868,178 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008069992A2 WO2008069992A2 (fr) 2008-06-12
WO2008069992A3 true WO2008069992A3 (fr) 2008-07-31

Family

ID=39492815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024681 WO2008069992A2 (fr) 2006-12-01 2007-11-30 Procédé et trousse pour administration intracellulaire

Country Status (1)

Country Link
WO (1) WO2008069992A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086842A1 (en) * 2000-06-26 2002-07-04 Christian Plank Method for transfecting cells using a magnetic field
US20020138864A1 (en) * 1998-05-22 2002-09-26 Jae Yong Han Method for transfection of avian primordial germ cells
US20050095578A1 (en) * 2003-10-31 2005-05-05 Koller Manfred R. Method and apparatus for cell permeabilization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020138864A1 (en) * 1998-05-22 2002-09-26 Jae Yong Han Method for transfection of avian primordial germ cells
US20020086842A1 (en) * 2000-06-26 2002-07-04 Christian Plank Method for transfecting cells using a magnetic field
US20050095578A1 (en) * 2003-10-31 2005-05-05 Koller Manfred R. Method and apparatus for cell permeabilization

Also Published As

Publication number Publication date
WO2008069992A2 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2009126655A3 (fr) Reprogrammation d’une cellule par induction d’un gène pluripotent par utilisation d’un modulateur à petite molécule
AU2015213344B2 (en) Novel CC-1065 analogs and their conjugates
WO2007002385A3 (fr) Populations cellulaires mesodermiques et endodermiques definitives
ZA200801212B (en) Method and system for extending payment system via text messaging
EP1920356A4 (fr) Designation, reglage et decouverte de parametres de documents de feuilles de calcul electroniques
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007051169A3 (fr) Utilisation d'agents d'expansion de cellules b dans la generation d'anticorps
WO2009037266A3 (fr) Procédé de détection ou de quantification d'une mutation tronquante
WO2008054341A3 (fr) Procédé de bio-imagerie utilisant des nanocristaux de colorants fluorescents
WO2007104011A3 (fr) Inhibition de protrusion de microtubule dans des cellules cancereuses
WO2007012811A9 (fr) Marqueurs de cellules souches
WO2008066779A3 (fr) Dispositifs de microscopie électrochimique de balayage de courant alternatif de mesure de balayage de champ proche et procédés d'utilisation de ceux-ci
WO2007008249A3 (fr) Procede de fabrication de nanostructures metalliques
ZA200800241B (en) Stable aqueous dispersions of colour developer
GB2447199B (en) Method of splicing pile cages, set of components therefor, and assembled pile cages
WO2007092222A3 (fr) Procede de caracterisation d'un compose biologiquement actif
WO2008059007A3 (fr) Formulations aqueuses et leur utilisation
PL1683840T3 (pl) Odporne na redukcję pigmenty oparte na ferrycie cynkowym, sposób ich wytwarzania i ich zastosowanie
WO2008069992A3 (fr) Procédé et trousse pour administration intracellulaire
EP2049452A4 (fr) Poudre mélangée contenant une poudre de solution solide et corps fritté obtenu avec la poudre mélangée, poudre de cermet mélangée contenant une poudre de solution solide et cermet obtenu à l'aide du cermet mélangé, et leurs procédés de fabrication
GB0617073D0 (en) System and method for automatically updating business informaion reports
WO2005103229A3 (fr) Mitochondries trasngeniques, cellules et organismes transmitochondriaux et procedes de production associes
WO2008070459A3 (fr) Nanoparticules enrobées pour des systèmes aqueux
WO2007075812A3 (fr) Methode d'utilisation de cellules hepatiques progenitrices pour traiter certains dysfonctionnements du foie
TW200630357A (en) N-heterocyclylphthaldiamides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862392

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07862392

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载